Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 8, 2006, Pages 2960-2966

  Akintoye, Sunday O ^a,b   Kelly, Marilyn H ^a   Brillante, Beth ^a   Cherman, Natasha ^a   Turner, Sarah ^a   Butman, John A ^a   Robey, Pamela G ^a   Collins, Michael T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CABERGOLINE; CYCLIC AMP; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; PROTEIN GSP; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ACROMEGALY; ADOLESCENT; ADULT; ALBRIGHT SYNDROME; ARTICLE; BONE DISEASE; BONE METABOLISM; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FIBROUS DYSPLASIA; HEALTH CENTER; HUMAN; HYPOPHYSIS; MALE; ORGAN SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING;

EID: 33747666886     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2661     Document Type: Article

References (24)

1. McCune DJ 1936 Osteitis fibrosa cystica: the case of a nine-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 52:743-744
2. Albright F, Butler AM, Hampton AO, Smith P 1937 Syndrome characterized by osteitis fibrosa disseminata, areas, of pigmentation, and endocrine dysfunction, with precocious puberty in females: report of 5 cases. N Engl J Med 216:727-746
3. Collins MT 2004 McCune-Albright syndrome. Orphanet Online Database of Rare Diseases (http://www.orpha.net), INSERM SCII; Paris
4. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
5. Schwindinger WF, Francomano CA, Levine MA 1992 Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152-5156
6. Spiegel AM 1997 The molecular basis of disorders caused by defects in G proteins. Horm Res 47:89-96
7. Ringel MD, Schwindinger WF, Levine MA 1996 Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 75:171-184
8. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT 2002 Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 87:5104-5112
9. Uwaifo GI, Robey PG, Akintoye SO, Collins MT 2001 Clinical picture: fuel on the fire. Lancet 357:2011
10. Ueland T 2005 GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 152:327-332
11. Spagnoli A, Rosenfeld RG 1996 The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors. Endocrinol Metab Clin North Am 25:615-631
12. Grinspoon S, Clemmons D, Swearingen B, Klibanski A 1995 Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 80:927-932
13. Ruggieri P, Sim FH, Bond JR, Unni KK 1994 Malignancies in fibrous dysplasia. Cancer 73:1411-1424
14. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC 2005 An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 20:219-226
15. Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K, Auff E 1999 A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 140:677-680
16. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL 1999 The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186-1196
17. Premawardhana LD, Vora JP, Mills R, Scanlon MF 1992 Acromegaly and its treatment in the McCune-Albright syndrome. Clin Endocrinol (Oxf) 36:605-608
18. Gorlin RJ, Cohen MM, Levin LS 1990 Syndromes of the head and neck. 3rd ed. New York: Oxford University Press
19. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
20. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
21. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S 2000 Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85:2958-2961
22. Wilson ME 2000 Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys. J Clin Endocrinol Metab 85:1557-1562
23. Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A 2002 Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf) 57:385-390
24. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ 2003 Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650-5655